Genmab reports anti-tumor activity of rinatabart sesutecan in advanced endometrial cancer
Genmab announced new data demonstrating that its investigational drug rinatabart sesutecan (Rina-S) achieved anti-tumor activity in patients with advanced endometrial cancer who were heavily pretreated.
Genmab has released new clinical data for its investigational drug rinatabart sesutecan (Rina-S). The findings indicate that the drug demonstrated anti-tumor activity in a patient population suffering from advanced endometrial cancer, who had previously undergone extensive treatment.
The data, presented at a scientific meeting, specifically highlights the drug's effect on patients who had received multiple prior lines of therapy. These results suggest a potential new avenue for treating this difficult-to-manage form of cancer.
Rinatabart sesutecan is part of the antibody-drug conjugate (ADC) class of therapies. Genmab is continuing its clinical development program to further assess the drug's safety and efficacy profile, aiming to introduce novel treatment options for cancer patients.
Future clinical studies and patient enrollment will be crucial to confirm the overall clinical benefit of Rina-S and its future role in cancer care.